ReviewJournal of neuroendocrinology2012
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.
Review in Journal of neuroendocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 213 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
213 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the pharmacological modulation of autobiographical memory specificity.Frontiers in psychology · 2022Pooled it
- Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.Translational psychiatry · 2017Trial
- Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.American journal of medical genetics. Part A · 2017Trial
- Oxytocin administration enhances controlled social cognition in patients with schizophrenia.Psychoneuroendocrinology · 2014Trial
- Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction.Psychoneuroendocrinology · 2014Trial
- Cyclic Peptides in Modern Drug Discovery: Trends and Therapeutic Directions.Journal of medicinal chemistry · 2026Review
- Structural elucidation of succinimide-derived hydrolytic isomers of atosiban using a conventional CID-based Asp/IsoAsp discrimination strategy.RSC advances · 2026Article
- Genetic pathways linking oxytocin-vasotocin hypothalamic subunit architecture with psychiatric and metabolic traits.Molecular psychiatry · 2026Article
- Photocaged Oxytocin and Vasopressin Probes to Decipher Neuropeptide Signalling With High Spatiotemporal Resolution.Angewandte Chemie (International ed. in English) · 2026Article
- Early life adversity, oxytocin system alterations, and addiction vulnerability: a narrative review.Psychopharmacology · 2026Review
- The Oxytocin Receptor in Spermatozoa May Originate From Both Spermatogenesis and Epididymal Maturation, and Regulates Capacitation.Andrology · 2026Article
- Molecular basis of antagonism of the dimeric human arginine vasopressin receptor 1A.Nature communications · 2026Article
- Expression and Function of Vasopressin Receptors in the HT-29 Cell Line.Current molecular medicine · 2026Article
- Peptides in the Diagnosis and Treatment of Pancreatic Cancer and Other Pancreatic Diseases from Basic Research to Clinical Translation.Drug design, development and therapy · 2026Review
- Acute administration of Manning compound during the spawning period reduces reproductive success in female zebrafish.Frontiers in endocrinology · 2026Article
- Vasopressin-to-oxytocin receptor crosstalk in the preoptic area underlying parental behaviors in male mice.Nature communications · 2025Article
- The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.British journal of pharmacology · 2025Review
- Regional differences in oxytocin and vasopressin 1a receptor functionality in mouse embryonic brain development.Neuroscience letters · 2025Article
- Fluorescent Peptide Tracers for Simultaneous Oxytocin Receptor Activation and Visualization.Angewandte Chemie (International ed. in English) · 2025Article
- Oxytocin modulates respiratory heart rate variability through a hypothalamus-brainstem-heart neuronal pathway.Nature neuroscience · 2025Article
153 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V(1a), V(1b) and V(2) receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V(1b) receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V(1a) agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V(2) /V(1a) antagonist, conivaptan and the V(2) antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V(1a), V(1b) and V(2) antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.